DNA-Encoded Library (DEL) technology involves a novel affinity selection process that integrates chemistry, biology, bioinformatics and computational chemistry to facilitate a rapid drug discovery process, allowing access to more chemical space with lower cost. In contrast to high throughput screening, DEL requires a very small amount of target protein and minimum assay development. More importantly, …Read More >

March 4, 2020 – By going commercial, DNA Encoded Library (DEL) technology facilitates rapid discovery and provides access to more chemical entities at lower cost. Over the years, DEL has become a disruptive drug discovery technology in comparison to traditional high-throughput screening (HTS) where it allows expedition of early stage drug discovery. However, DEL platforms don’t succeed …Read More >

WuXi AppTec  provides a one-stop solution for DEL services from target to hit series. Our extended platform enables overall planning and management of protein production, DEL library production, affinity selection, data analysis, hit validation and structural biology for further optimization.

DELopen platform is dedicated to the development and application of DEL technology in drug discovery. Free access to DEL, data sharing. DELopen encourages an open, community-based approach to data sharing and exploration of the capabilities of DEL technology. We envision that DELopen will help academia benefits from the efficiency of DEL and unlock the full …Read More >